Parkinson's disease: Medical and surgical treatment

Neurologic Clinics

Volumn 19, Issue 3, 2001, Pages 579-605

  Ahlskog, J Eric ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BENSERAZIDE; BENZATROPINE MESILATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DEXTROMETHORPHAN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PERGOLIDE; PERGOLIDE MESILATE; PRAMIPEXOLE; PROPRANOLOL; RILUZOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DYSKINESIA; HUMAN; MAXIMUM TOLERATED DOSE; NERVE DEGENERATION; NEUROSURGERY; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TOXICITY; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0034838406     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70036-0     Document Type: Article

References (156)

1. Levodopa in the treatment of Parkinson's disease: A consensus meeting
2. Cerebral transplantation for Parkinson's disease: Current progress and future prospects
3. The evaluation and treatment of Parkinson's disease
4. Medical treatment of later-stage motor problems of Parkinson's disease
5. Treatment of motor complications in advancing Parkinson's disease: Which drugs and when?
6. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
7. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease
8. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing
9. Brain peroxidase and catalase in Parkinson's disease
10. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: A consecutive series of 62 patients
11. Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-Year results of a pilot study
12. Levodopa-induced dyskinesia: Facts and fancy. What does the MPTP monkey model tell us?
13. Pallidal stimulation for Parkinson's disease: Two targets?
14. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus
15. Increased life expectancy resulting from addition of 1-deprenyl to Madopar treatment in Parkinson's disease: A long-term study
16. Does levodopa aggravate Parkinson's disease?
17. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease
18. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease
19. Interaction of D-1 and D-2 dopamine receptors in the expression of dopamine agonist induced behaviors
20. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: Results of a randomized blinded pilot study
21. The occurrence of motor fluctuations in parkinsonian patients treated long-term with levodopa: Role of early treatment and disease progression
22. Stimulation of both D-1 and D-2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: A neurophysiological study
23. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease
24. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson's disease
25. Levodopa, fertility and longevity
26. Factors that influence the occurrence of response variations in Parkinson's disease
27. Primate models of movement disorders of basal ganglia origin
28. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
29. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
30. Present mortality in Parkinson's disease: The ratio of observed to expected deaths with a method to calculate expected deaths
31. Multi-center study of Parkinson mortality with early versus later dopa treatment
32. Selegiline and mortality in subjects with Parkinson's disease: A longitudinal community study
33. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients
34. Acute and chronic effects of anteromedial globus pallidus stimulation in Parkinson's disease
35. Double-blind controlled trial of embryonic dopaminergic tissue transplants in advanced Parkinson's disease
36. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
37. Double-blind controlled trial of human embryonic dopaminergic tissue transplants in advanced Parkinson's disease: Clinical outcomes
38. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease
39. Slow recovery of human brain MAO B after L-deprenyl (Selegiline) withdrawal
40. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients
41. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease
42. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
43. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease
44. Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy
45. Behavioral correlations of dopamine receptor activation
46. Neurological and neuropsychological complications of bilateral contemporaneous pallidotomy in Parkinson's disease
47. Early combination of bromocriptine and levodopa in Parkinson's disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage
48. Young-onset Parkinson's disease: A clinical review
49. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease
50. Severe spontaneous dyskinesias: A disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease
51. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
52. Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft
53. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease
54. Evaluatin of surgery for Parkinson's disease: A report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
55. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease
56. Long-term administration of l-dopa does not damage dopaminergic neurons in the mouse
57. The Sydney multicentre study of Parkinson's disease: A randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa
58. Parkinsonism treated with levodopa: Progression and mortality
59. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor
60. Overview of morphological changes in Parkinson's disease
61. Levodopa in Parkinson's disease: A long-term appraisal of mortality
62. Computer-assisted stereotactic ventralis lateralis thalamotomy with microelectrode recording control in patients with Parkinson's disease
63. Glutathione peroxidase activity in Parkinson's disease brain
64. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study
65. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease
66. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease
67. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation
68. Ineffective subthalamic nucleus stimulation in levodopa-resistant postischemic parkinsonism
69. Opposite motor effects of pallidal stimulation in Parkinson's disease
70. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease
71. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease
72. Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation
73. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease
74. Surgery for Parkinson's disease: A critical evaluation of the state of the art
75. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
76. Statistical prediction of the optimal site for thalamotomy in parkinsonian tremor
77. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy
78. Comparison of pergolide and bromocriptine therapy in parkinsonism
79. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
80. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation
81. Update on fetal transplantation: The Swedish experience
82. Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson's disease
83. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease
84. Long-term follow-up of early dopa treatment in Parkinson's disease
85. Mortality of patients with Parkinson's disease treated with levodopa
86. Glia conditioned medium protects fetal rat midbrain neurons in culture from l-dopa toxicity
87. Glia protect fetal midbrain dopamine neurons in culture from l-dopa toxicity through multiple mechanisms
88. Neurotrophic effects of l-dopa in postnatal midbrain dopamine neuron/cortical astrocyte cocultures
89. Neurotoxicity of levodopa on catecholamine-rich neurons
90. Unilateral radiofrequency lesion versus electrostimulation of posteroventral pallidum: A prospective randomized comparison
91. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease
92. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture
93. Pergolide in the treatment of Parkinson's disease
94. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease
95. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow up
96. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease
97. L-dopa therapy of Parkinson's disease: Plasma l-dopa concentration, therapeutic response, and side effects
98. Levodopa-induced dyskinesia and thalamotomy
99. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of l-dopa
100. The "on-off" phenomenon in Parkinson's disease: Relation to levodopa absorption and transport
101. Oxidation reactions in Parkinson's disease
102. Ropinirole delays risk for levodopa-induced dyskinesia in PD
103. The effect of deprenyl and levodopa on the progression of Parkinson's disease
104. Effect of selegiline on mortality in patients with Parkinson's disease: A meta-analysis
105. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias
106. High-frequency stimulation of the globus pallidus for treatment of Parkinson's disease
107. Selegiline delays the onset of disability in de novo parkinsonian patients
108. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset
109. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report
110. Effect of deprenyl on the progression of disability in early Parkinson's disease
111. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
112. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
113. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients not requiring levodopa
114. A randomized controlled trial comparing the agonist pramipexole with levodopa as initial dopaminergic treatment for Parkinson's disease
115. De novo administration of ropinirole and bromocriptine induces less dyskinesias than l-dopa in the MPTP-treated marmoset
116. Binding and functional potencies of bromocriptine, pramipexole, pergolide and ropinirole at D1, D2 and D3 receptors
117. Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease
118. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
119. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists
120. Low-dose l-dopa therapy in Parkinson's disease: A 6-year follow-up study
121. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects: Long term results of the PRADO study
122. Young onset Parkinson's disease
123. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period
124. Is levodopa toxic to human substantia nigra?
125. Chronic low-dose levodopa therapy in Parkinson's disease: An argument for delaying levodopa therapy
126. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
127. Dopamine agonists as primary treatment in Parkinson's disease
128. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5 year follow up
129. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial
130. Response fluctuations in Parkinson's disease
131. Functional and structural consequences of long-term dietary l-dopa treatment in mice
132. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in striatum of Parkinson's disease brain
133. The role of D-1 and D-2 receptors
134. Young-onset Parkinson's disease revisited - Clinical features, natural history, and mortality
135. Transplantation of embryonic porcine mesencephalic tissue in patients with PD
136. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor
137. Bilateral chronic electrostimulation of ventroposterolateral pallidum: A new therapeutic approach for alleviating all parkinsonian symptoms
138. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study
139. Five years' treatment of Parkinson's disease with levodopa: Therapeutic results and survival of 100 patients
140. Dopa and dopamine cause cultured neuronal death in the presence of iron
141. Influence of treatment on the natural history of Parkinson's disease
142. Pharmacologic profile of ropinirole: A nonergoline dopamine agonist
143. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County Project
144. Comparative review of dopamine receptor agonists in Parkinson's disease
145. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease
146. Amantadine for levodopa-induced dyskinesias
147. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
148. A trial of dextromethorphan in parkinsonian patients with motor response complications
149. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
150. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease
151. Bromocriptine, selective D-2 dopamine receptor agonists and D-1 dopaminergic tone
152. D-1 dopamine receptor activation required for postsynaptic expression of D-2 agonist effects
153. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease
154. Autopsy findings in parkinsonism following treatment with levodopa
155. Mortality among parkinson patients treated with l-dopa combined with a decarboxylase inhibitor